Pharma Sector

The said acquisition is for a total consideration of Rs28.05 crore.

Shailesh Gadre, Founder of GCV Life was the exclusive advisor for the transaction

Post purchase of shares, the target entity would become a wholly owned subsidiary of SPL.

Alkem Lab, Pfizer, and Divis Lab were also among the top gainers. Cipla, Granules India, and Lupin were trading in the red.

The pharma company paid $99.279 million for the entire transaction.

The consideration for this acquisition is set as an upfront payment plus performance and milestone-based earn-outs over the next four years.

Their primary business activity is to invest funds with the objective of achieving appreciation of capital invested.

Their primary business activity is to invest funds to achieve an appreciation of the capital invested.

Further, before the proposed combination, GSKAPL will acquire the trademarks about “Iodex†and “Ostocalcium†brands in India .

Sun Pharma performed as top gainer surging by 3% after hitting 52-week high Rs861.50 per piece.